دوره 7، شماره 2 - ( 1401 )
دوره 7 شماره 2 صفحات 101-95 |
برگشت به فهرست نسخه ها
موژان اسدی1 
، شایان مردی2 ، عرفان بصیرت* 3
، شایان مردی2 ، عرفان بصیرت* 3
1- گروه داخلی، مرکز پزشکی آموزشی و درمانی شهید رجایی، کرج، ایران
2- کمیته تحقیقات دانشجویی، دانشکده پزشکی, دانشگاه علوم پزشکی اراک، اراک، ایران.
3- کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی البرز، کرج، ایران. ،p.mardi.med@gmail.com
2- کمیته تحقیقات دانشجویی، دانشکده پزشکی, دانشگاه علوم پزشکی اراک، اراک، ایران.
3- کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی البرز، کرج، ایران. ،
چکیده: (1220 مشاهده)
مقدمه: لنفوم سلول B بزرگ منتشر (DLBCL) شایع ترین نوع لنفوم غیر هوچکین (NHL) در سراسر جهان بوده و حدود 22 درصد از موارد تازه تشخیص داده شده NHL سلول B را تشکیل می دهد. تعیین پروگنوز بیماران و انتخاب رژیم درمانی مناسب مورد بحث بسیاری از پژوهش ها بوده است. در این مقاله به بررسی یک مورد بیمار diffuse large B cell lymphoma با متاستاز های گسترده ی بسیار نادر در PET-CT scan می پردازیم که به خط اول درمانی مطرح شده در گایدلاین های معتبر پاسخ نداده اما پاسخ بیماری به خط دوم درمان (رژیم R-ICE) بسیار قابل توجه بوده است.
نتیجه گیری: این کیس نشان می دهد که احتمالا در مواردی که درگیری وسیع در PET-CT scan بیمار مطرح بوده و پروگنوز بیمار بر اساس IPI ضعیف تلقی شود، می توان در ابتدا از رژیم R-ICE استفاده کرد و خط اول درمان با R-CHOP را برای بیمار در نظر نگرفت.
نتیجه گیری: این کیس نشان می دهد که احتمالا در مواردی که درگیری وسیع در PET-CT scan بیمار مطرح بوده و پروگنوز بیمار بر اساس IPI ضعیف تلقی شود، می توان در ابتدا از رژیم R-ICE استفاده کرد و خط اول درمان با R-CHOP را برای بیمار در نظر نگرفت.
شماره‌ی مقاله: 4
واژه‌های کلیدی: لنفوم سلول B بزرگ منتشر، PET/CT scan، پروگنوز، رژیم درمانی R-ICE، رژیم درمانی R-CHOP
نوع مقاله: گزارش مورد |
موضوع مقاله:
بهداشت و ايمني
دریافت: 1401/6/10 | پذیرش: 1401/6/21 | انتشار: 1401/12/27
دریافت: 1401/6/10 | پذیرش: 1401/6/21 | انتشار: 1401/12/27
فهرست منابع
1. 1, Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, et al. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leukemia & lymphoma. 2019;60(4):894-903. [DOI:10.1080/10428194.2018.1515940]
2. Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, et al. NCCN Guidelines® insights: b-cell lymphomas, version 5.2021: featured updates to the nccn guidelines. Journal of the National Comprehensive Cancer Network. 2021;19(11):1218-30. [DOI:10.6004/jnccn.2021.0054]
3. Ruiz IC, Martelli M, Sehn LH, Vitolo U, Nielsen TG, Sellam G, et al. Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA. Clinical Lymphoma Myeloma and Leukemia.2022;22(8):e804-e14. [DOI:10.1016/j.clml.2022.04.010]
4. Tilly H, Da Silva MG, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2015;26:v116-v25. [DOI:10.1093/annonc/mdv304]
5. Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood, The Journal of the American Society of Hematology.2015;125(1):22-32. [DOI:10.1182/blood-2014-05-577189]
6. Jalili J, Vahedi A, Danandehmehr A, Aynechi P, Esfahani A, Roosta Y, et al. Subtype distribution of lymphomas in northwestern Iran: a retrospective analysis of 659 cases according to World Health Organization classification. BMC cancer.2022;22(1):1059. [DOI:10.1186/s12885-022-10132-2]
7. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-A2001. Blood. 2006;107(1):265-76. [DOI:10.1182/blood-2005-06-2508]
8. Jamil MO, Mehta A. Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy. Expert review of hematology. 2016;9(5):471-A7. [DOI:10.1586/17474086.2016.1146584]
9. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. Journal of clinical oncology. 2010;28(14):2373-80. [DOI:10.1200/JCO.2009.26.2493]
10. Ruppert AS, Dixon JG, Salles G, Wall A, Cunningham D, Poeschel V, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. A2020;135(23):2041-8. [DOI:10.1182/blood.2019002729]
11. Shi Q, Schmitz N, Ou F-S, Dixon JG, Cunningham D, Pfreundschuh M, et al. Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). Journal of Clinical Oncology. 2018;36(25):2593. [DOI:10.1200/JCO.2018.77.9124]
12. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, The Journal of the American Society of Hematology. 2014;123(6):837-A42.
13. Harkins RA, Chang A, Patel SP, Lee MJ, Goldstein JS, Merdan S, et al. Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. Expert review of hematology. A2019;12(11):959-73. [DOI:10.1080/17474086.2019.1660159]
14. Toledano MN, Desbordes P, Banjar A, Gardin I, Vera P, Ruminy P, et al. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 2018;45:680-8. [DOI:10.1007/s00259-017-3907-x]
15. Sun R, Medeiros LJ, Young KH. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Modern Pathology. 2016;29(10):1118-42. [DOI:10.1038/modpathol.2016.92]
16. Desai SH, Pederson L, LaPlant B, Mwangi R, Maurer M, Young JR, et al. PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood cancer journal. 2022;12(5):78. [DOI:10.1038/s41408-022-00649-x]
17. Li C, Yu H, Chen X, Han S, Peng S, Lei T, et al. The Prognostic Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Analyses of Metabolic Response Rates in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients. Frontiers in Oncology. 2022;12. [DOI:10.3389/fonc.2022.772773]
18. Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas R-O, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. European journal of nuclear medicine and molecular imaging. A2014;41:2017-22. [DOI:10.1007/s00259-014-2822-7]
19. Takasaki H, Yamamoto W, Ishii Y, Takahashi H, Watanabe R, Harada T, et al. Post-treatment PET-CT Findings may Predict the Prognosis of DLBCL with a Bulky Mass. Indian Journal of Hematology and Blood Transfusion. A2015;31:346-51. [DOI:10.1007/s12288-014-0479-9]
20. Im H-J, Bradshaw T, Solaiyappan M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better? Nuclear medicine and molecular imaging. A 2018;52:5-15. [DOI:10.1007/s13139-017-0493-6]
21. Adams HJ, Kwee TC. Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Critical reviews in oncology/hematology. A 2016;106:55-63. [DOI:10.1016/j.critrevonc.2016.07.003]
22. Schmitz C, Hüttmann A, Müller SP, Hanoun M, Boellaard R, Brinkmann M, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: post-hoc analysis from the PETAL trial. European Journal of Cancer. 2020;124:25-36. [DOI:10.1016/j.ejca.2019.09.027]
23. Kostakoglu L, Mattiello F, Martelli M, Sehn LH, Belada D, Ghiggi C, et al. Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. Haematologica. 2020. [DOI:10.3324/haematol.2021.278663]
24. Mikhaeel NG, Smith D, Dunn JT, Phillips M, Møller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. European journal of nuclear medicine and molecular imaging. 2016;43:1209-19. [DOI:10.1007/s00259-016-3315-7]
25. Ceriani L, Milan L, Martelli M, Ferreri AJ, Cascione L, Zinzani PL, et al. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood, The Journal of the American Society of Hematology. 2018;132(2):179-86. [DOI:10.1182/blood-2018-01-826958]
26. Delaby G, Hubaut M-A, Morschhauser F, Besson A, Huglo D, Herbaux C, et al. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline 18F-FDG PET-CT. Leukemia & Lymphoma. 2020;61(7):1584-91. [DOI:10.1080/10428194.2020.1728750]
27. Zhang YY, Song L, Zhao MX, Hu K. A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and% ΔSUVmax. Cancer medicine. 2019;8(11):5137-47. [DOI:10.1002/cam4.2284]
28. Michaud L, Bantilan K, Mauguen A, Moskowitz CH, Zelenetz AD, Schöder H. Prognostic value of 18F-FDG PET/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen. Journal of Nuclear Medicine. 2022. [DOI:10.2967/jnumed.122.264740]
29. Schöder H, Polley M-YC, Knopp MV, Hall N, Kostakoglu L, Zhang J, et al. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. A 2020;135(25):2224-34. [DOI:10.1182/blood.2019003277]
30. Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. Journal of Clinical Oncology. 2018;36(20):2024-34. [DOI:10.1200/JCO.2017.76.8093]
31. Guo B, Tan X, Ke Q, Cen H. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis. PloS one. 2019;14(1):e0210224. [DOI:10.1371/journal.pone.0210224]
32. Yang D-H, Min J-J, Song H-C, Jeong YY, Chung W-K, Bae S-Y, et al. Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. European journal of cancer. A 2011;47(9):1312-8. [DOI:10.1016/j.ejca.2010.12.027]
33. Kitajima K, Okada M, Yoshihara K, Tokugawa T, Sawada A, Yoshihara S, et al. Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP. Oncotarget. 2019;10(52):5403. [DOI:10.18632/oncotarget.27103]
34. Senjo H, Hirata K, Izumiyama K, Minauchi K, Tsukamoto E, Itoh K, et al. High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma. Blood Advances. 2020;4(10):2286-96. [DOI:10.1182/bloodadvances.2020001816]
35. Barrington SF, Meignan M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. Journal of Nuclear Medicine. 2019;60(8):1096-102. [DOI:10.2967/jnumed.119.227249]
36. Cottereau A-S, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT. Annals of Oncology. 2021;32(3):404-11. [DOI:10.1016/j.annonc.2020.11.019]
37. Jo J-H, Chung HW, Kim S-Y, Lee MH, So Y. FDG PET/CT Maximum Tumor Dissemination to Predict Recurrence in Patients with Diffuse Large B-Cell Lymphoma. Nuclear Medicine and Molecular Imaging. 2022:1-8. [DOI:10.1007/s13139-022-00782-2]
38. Nyilas R, Farkas B, Bicsko RR, Magyari F, Pinczes LI, Illes A, et al. Interim PET/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients. International Journal of Hematology. 2019;110:331-9. [DOI:10.1007/s12185-019-02690-2]
39. Tokola S, Kuitunen H, Turpeenniemi‐Hujanen T, Kuittinen O. Interim and end‐of‐treatment PET‐CT suffers from high false‐positive rates in DLBCL: Biopsy is needed prior to treatment decisions. Cancer Medicine. 2021;10(9):3035-44. [DOI:10.1002/cam4.3867]
40. Mikhaeel NG, Heymans MW, Eertink JJ, De Vet HC, Boellaard R, Dührsen U, et al. Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International Metabolic Prognostic Index. Journal of Clinical Oncology. 2022;40(21):2352. [DOI:10.1200/JCO.21.02063]
41. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, The Journal of the American Society of Hematology. 2010;116(12):2040-5. [DOI:10.1182/blood-2010-03-276246]
42. Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. The Lancet. 2013;381(9880):1817-26. [DOI:10.1016/S0140-6736(13)60313-X]
43. Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). The lancet oncology. 2012;13(12):1250-9. [DOI:10.1016/S1470-2045(12)70481-3]
44. Sehn LH, Martelli M, Trněný M, Liu W, Bolen CR, Knapp A, et al. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. Journal of hematology & oncology. 2020;13:1-9. [DOI:10.1186/s13045-020-00900-7]
45. Bartlett NL, Wilson WH, Jung S-H, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. Journal of clinical oncology. 2019;37(21):1790. [DOI:10.1200/JCO.18.01994]
46. Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, et al. A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. Blood Advances. 2021;5(4):984-93. [DOI:10.1182/bloodadvances.2020002567]
47. Rassy E, Danu A, Ibrahim T, Lazarovici J, Ghez D, Michot J-M, et al. Outcomes of transplant-eligible patients with relapsed or refractory diffuse large b-cell lymphoma after second-line salvage chemotherapy: the Gustave Roussy experience. Clinical Lymphoma Myeloma and Leukemia. 2021;21(4):e373-e80. [DOI:10.1016/j.clml.2020.11.008]
48. Tanaka N, Imai Y, Yoshinaga K, Shiseki M, Tanaka J. Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. Annals of Hematology. 2020;99:2577-86. [DOI:10.1007/s00277-020-04267-0]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |